Hedgehog signaling and the glioma-associated oncogene in cancer radioresistance
Frontiers in Cell and Developmental Biology · 13.11.2023 · 11
DOI: 10.3389/fcell.2023.1257173 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 13.11.2023. Verfasst von Li Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Department, The 1st Hospital of Jilin University, Changchun, China. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Jilin Province.
Abstract (Originalsprache)
Tumor radioresistance remains a key clinical challenge. The Hedgehog (HH) signaling pathway and glioma-associated oncogene (GLI) are aberrantly activated in several cancers and are thought to contribute to cancer radioresistance by influencing DNA repair, reactive oxygen species production, apoptosis, autophagy, cancer stem cells, the cell cycle, and the tumor microenvironment. GLI is reported to activate the main DNA repair pathways, to interact with cell cycle regulators like Cyclin D and Cyclin E, to inhibit apoptosis via the activation of B-cell lymphoma-2, Forkhead Box M1, and the MYC proto-oncogene, to upregulate cell stemness related genes (Nanog, POU class 5 homeobox 1, SRY-box transcription factor 2, and the BMI1 proto-oncogene), and to promote cancer stem cell transformation. The inactivation of Patched, the receptor of HH, prevents caspase-mediated apoptosis. This causes some cancer cells to survive while others become cancer stem cells, resulting in cancer recurrence. Combination treatment using HH inhibitors (including GLI inhibitors) and conventional therapies may enhance treatment efficacy. However, the clinical use of HH signaling inhibitors is associated with toxic side effects and drug resistance. Nevertheless, selective HH agonists, which may relieve the adverse effects of inhibitors, have been developed in mouse models. Combination therapy with other pathway inhibitors or immunotherapy may effectively overcome resistance to HH inhibitors. A comprehensive cancer radiotherapy with HH or GLI inhibitor is more likely to enhance cancer treatment efficacy while further studies are still needed to overcome its adverse effects and drug resistance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nephrology Department, The 1st Hospital of Jilin University, Changchun, China.
- General Surgery Center, Department of Thyroid Surgery, The 1st Hospital of Jilin University, Changchun, China.
Förderung
- Natural Science Foundation of Jilin Province
Zitieren
APA
Zhang, L., Zhang, Y., Li, K., & Xue, S. (2023). Hedgehog signaling and the glioma-associated oncogene in cancer radioresistance. Frontiers in Cell and Developmental Biology, 11. https://doi.org/10.3389/fcell.2023.1257173
Vancouver
Zhang L, Zhang Y, Li K, Xue S. Hedgehog signaling and the glioma-associated oncogene in cancer radioresistance. Frontiers in Cell and Developmental Biology. 2023;11. doi:10.3389/fcell.2023.1257173
BibTeX
@article{Zhang2023,
author = {Zhang, Li and Zhang, Yuhan and Li, Kaixuan and Xue, Shuai},
title = {Hedgehog signaling and the glioma-associated oncogene in cancer radioresistance},
journal = {Frontiers in Cell and Developmental Biology},
year = {2023},
volume = {11},
doi = {10.3389/fcell.2023.1257173}
}
EUVIMED